智慧睡眠醫學™（Smart Sleep Medicine™）的先驅 ProSomnus Sleep Technologies（以下簡稱「ProSomnus」），以及睡眠醫學領域首屈一指的數位健康與遠距監測平台 MonitAir, LLC（以下簡稱「MonitAir」），宣布展開合作，旨在為阻塞性睡眠呼吸中止症（OSA）患者提供連網、縱向追蹤及個人化的照護。透過此次合作，開立 ProSomnus RPMO₂ 處方的醫療服務提供者 […]
Tag: PROSOMNUS
ProSomnus 獲得 Catalio Capital 3,800 萬美元投資，以擴大智慧睡眠醫學業務規模
ProSomnus Sleep Technologies announced a strategic investment from Catalio Capital Management, L.P. to accelerate the global expansion of its technology-enabled sleep health platform. Under the agreement, Catalio, a premier healthcare-focused investment firm, has committed up to $38 million to advance development of next-generation remote patient monitoring (RPM) and proprietary sleep […]
ProSomnus 宣布戰略計畫取得重大進展
ProSomnus Sleep Technologies announced significant progress on strategic programs. The key feature is the successful FDA registration of the company’s HWO2 buccal mucosal wellness oximeter. The ProSomnus HWO2 Device enables patients to monitor their nightly health and wellness during sleep, specifically, blood oxygen saturation, pulse rate and overall use time, […]
ProSomnus Introduces EVO Guided for the Treatment of Obstructive Sleep Apnea
ProSomnus Sleep Technologies announces EVO Guided. EVO Guided is a new precision, custom oral device for the treatment of Obstructive Sleep Apnea (“OSA”). FDA cleared, patented and covered by most medical insurances, EVO Guided is the first oral device bioengineered to dilate the oropharynx and the velopharynx for optimal therapeutic […]
ProSomnus 宣布重組完成後創下營收新高
ProSomnus Sleep Technologies announced record revenues for the quarter that ended 六月 30, 2024, as it formally emerged from reorganization on 八月 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% […]
ProSomnus Files Chapter 11 Bankruptcy to Secure Financial Future
ProSomnus, Inc. announced it has initiated a voluntary restructuring process under Chapter 11 of the U.S. Bankruptcy Code to reorganize and strengthen its capital structure going forward, improve financial flexibility and better position the company for long-term success. In connection with this process, the Company has secured the support of […]
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
ProSomnus, Inc. has announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are also participating in the financing. A description of the terms of the offering can […]
ProSomnus to Design Head-to-Head Clinical Trial: OAT vs. Hypoglossal Nerve Stimulation
ProSomnus, Inc. announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HGNS) in treating patients with severe OSA. The clinical trial plans follow updated results from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT), a prospective, independent, head-to-head, crossover […]
ProSomnus Survey Finds 71% of Snorers Have Never Consulted a Healthcare Professional
ProSomnus, Inc. released the results of a survey conducted in partnership with Prodege, a cutting-edge consumer marketing and insights platform, on the major obstacles to identifying and treating snoring and OSA, including a lack of awareness of where to seek medical advice. Key findings of the survey of 1,000 people […]
ProSomnus Presents Further OAT OSA Validation Data at AADSM and ATS
ProSomnus, Inc. announced the presentation of four abstracts at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held 五月 19-21 in Philadelphia, Pennsylvania, and two abstracts at the American Thoracic Society (ATS) 2023 International Conference, held 五月 19-24 in Washington, D.C. The data presented at both meetings […]
